Skip to main content

Table 1 Clinical trials investigating the efficacy of ICI plus anti-angiogenesis therapy

From: Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

Trials Identifier Disease Treatment (arm of combination therapy) Phase Status
NCT03024437 RCC Atezolizumab + bevacizumab + entinostat I/II Recruiting
NCT03363867 OC Atezolizumab + bevacizumab + cobimetinib II Recruiting
NCT03472560 NSCLC/UC Avelumab + axitinib II Recruiting
NCT03395899 BC Atezolizumab + bevacizumab + cobimetinib II Recruiting
NCT02724878 NCCKC Atezolizumab + bevacizumab II Recruiting
NCT03386929 NSCLC Avelumab + axitinib + palbociclib I/II Recruiting
NCT03574779 OC TSR-042+ bevacizumab + Niraparib II Recruiting
NCT02921269 CC Atezolizumab + bevacizumab II Active, not recruiting
NCT03647956 NSCLC Atezolizumab + bevacizumab + carboplatin + pemetrexed II Recruiting
NCT02734004 OC/BC/SCLC/GC MEDI4736 + bevacizumab + olaparib I/II Recruiting
NCT03517449 EC Pembrolizumab + lenvatinib III Recruiting
NCT02572687 GC/GEJ/NSCLC/HCC MEDI4736 + ramucirumab I Active, not recruiting
NCT02839707 OC/FTC/PC Atezolizumab + bevacizumab + PLD II/III Recruiting
NCT03289533 HCC Avelumab + axitinib I Recruiting
NCT02210117 RCC Ipilimumab + bevacizumab I Active, not recruiting
NCT01950390 Melanoma Ipilimumab + bevacizumab II Active, not recruiting
NCT03394287 BC SHR-1210 + apatinib II Recruiting
NCT03417895 SCLC SHR-1210 + apatinib II Not yet recruiting
NCT03491631 Multiple solid tumors SHR-1210 + apatinib + SHR9146 I Not yet recruiting
NCT02942329 HCC/GC SHR-1210 + apatinib I/II Recruiting
NCT03671265 ESCC SHR-1210 + apatinib + radiation NA Not yet recruiting
NCT03359018 Osteosarcoma SHR-1210 + apatinib II Active, not recruiting
NCT03722875 HCC SHR-1210 + apatinib NA Not yet recruiting
NCT03502746 Mesothelioma Nivolumab + ramucirumab II Recruiting
NCT03606174 UC Nivolumab + sitravatinib II Recruiting
NCT02853331 RCC Pembrolizumab + axitinib III Active, not recruiting
NCT03680521 RCC Nivolumab + sitravatinib II Recruiting
NCT02493751 RCC Avelumab + axitinib I Active, not recruiting
NCT02684006 RCC Avelumab + axitinib III Active, not recruiting
NCT02366143 NSCLC Atezolizumab + bevacizumab + paclitaxel + carboplatin III Active, not recruiting
NCT00790010 Melanoma Ipilimumab + bevacizumab I Active, not recruiting
NCT 01633970 Multiple solid tumors Atezolizumab + bevacizumab I Active, not recruiting
  1. The details of Table 1 was obtained from Abbreviations: BC breast cancer, CC cervical cancer, EC endometrial cancer, ESCC esophageal squamous cell carcinoma, FTC fallopian tube cancer, GC gastric cancer, GEJ gastroesophageal junction adenocarcinoma, GIST gastrointestinal stromal tumor, HCC hepatocellular carcinoma, NA not applicable, NCCKC Non-clear cell kidney cancer, NSCLC non-small cell lung cancer, OC ovarian cancer, PC peritoneal cancer, PLD pegylated liposomal doxorubicin hydrochloride, RCC renal cell cancer, SCLC small cell lung cancer, UC urothelial cancer